Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine dose escalation for pain in opioid-dependent adults
ACTRN12614001038684Phase 4Completed
- Sponsor
- South Eastern Sydney Local Health District
- Start
- Oct 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, double-blind trial of buprenorphine and naloxone in pain and opioid use disorder (OUD) (3 arms), sponsored by South Eastern Sydney Local Health District. Primary endpoints: Pain threshold and Pain tolerance. Started Oct 2014; status: completed.
02
Drugs
buprenorphinenaloxone
03
Conditions
painopioid use disorder (OUD)
Beyond the preview
Go deeper on ACTRN12614001038684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001038684.